| Oscar Insurance Guidelines | Benlysta belimumab | 2025-12-01 |
| Oscar Insurance Guidelines | iDose TR (travoprost intracameral implant) | 2025-12-01 |
| Oscar Insurance Guidelines | Insulin Delivery Systems and Continuous Glucose Monitoring | 2025-12-01 |
| Oscar Insurance Guidelines | Restasis cyclosporine ophthalmic emulsion 0.05- | 2025-12-01 |
| Oscar Insurance Guidelines | Oscar Clinical Guideline: Direct Acting Antiviral Agents for Hepatitis C | 2025-12-01 |
| Oscar Insurance Guidelines | Oscar Clinical Guideline: azelaic acid 15% gel | 2025-12-01 |
| UHC UMR Medical and Drug | Benlysta® (Belimumab) – Commercial Medical Benefit Drug Policy | 2025-12-01 |
| UHC UMR Medical and Drug | Evenity® (Romosozumab-Aqqg) – Commercial Medical Benefit Drug Policy | 2025-12-01 |
| UHC UMR Medical and Drug | Ophthalmologic Complement Inhibitors – Commercial Medical Benefit Drug Policy | 2025-12-01 |
| UHC UMR Medical and Drug | Rebyota® (Fecal Microbiota, Live-Jslm) – Commercial Medical Benefit Drug Policy | 2025-12-01 |